PTSD Symptom Reports of Patients Evaluated for the New Mexico Medical Cannabis Program

Journal of Psychoactive Drugs

Volumn 46, Issue 1, 2014, Pages 73-77

  Greer, George R ^a   Grob, Charles S ^b   Halberstadt, Adam L ^c  

^a Private Practice   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cannabis; post traumatic; stress; tetrahydrocannabinol; THC; treatment

Indexed keywords

CANNABIS; PLANT EXTRACT;

ANALYSIS OF VARIANCE; ARTICLE; CLINICIAN ADMINISTERED POSTTRAUMATIC SCALE; HUMAN; MAJOR CLINICAL STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; POST HOC ANALYSIS; POSTTRAUMATIC STRESS DISORDER;

CANNABIS; HALLUCINOGENS; HUMANS; MEDICAL MARIJUANA; NEW MEXICO; PROGRAM EVALUATION; PSYCHOMETRICS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT OUTCOME;

EID: 84896870530     PISSN: 02791072     EISSN: 21599777     Source Type: Journal    
DOI: 10.1080/02791072.2013.873843     Document Type: Article

References (17)

1. Allsop, D.J.; Norberg, M.M.; Copeland, J.; Fu, S. & Budney, A.J. 2011. The Cannabis Withdrawal Scale development: Patterns and predictors of cannabis withdrawal and distress. Drug and Alcohol Dependence 119 (1-2): 123-9.
2. Blake, D.D.; Weathers, F.W.; Nagy, L.M.; Kaloupek, D.G.; Gusman, F.D.; Charney, D.S. & Keane, T.M. The development of a clinician-administered PTSD scale. Journal of Traumatic Stress 8: 75-90.
3. Bonn-Miller, M.O.; Vujanovic, A.A. & Drescher, K.D. 2011. Cannabis use among military veterans after residential treatment for posttraumatic stress disorder. Psychology of Addictive Behaviors 25 (3): 485-91.
4. Chhatwal, J.P.; Davis, M.; Maguschak, K.A. & Ressler, K.J. 2005. Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology 30: 516-24.
5. Cornelius, J.R.; Kirisci, L.; Reynolds, M.; Clark, D.B.; Hayes, J. & Tarter, R. 2010. PTSD contributes to teen and young adult cannabis use disorders. Addict Behav 35 (2): 91-4.
6. Cougle, J.R.; Bonn-Miller, M.O.; Vujanovic, A.A.; Zvolensky, M.J. & Hawkins, K.A. 2011. Posttraumatic stress disorder and cannabis use in a nationally representative sample. Psychology of Addictive Behaviors 25 (3): 554-8.
7. de Bitencourt, R.M.; Pamplona, F.A. & Takahashi R.N. 2013. A current overview of cannabinoids and glucocorticoids in facilitating extinction of aversive memories: Potential extinction enhancers. Neuropharmacology 64: 389-95.
8. Fraser, G.A. 2009. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neuroscience & Therapeutics 15 (1): 84-8.
9. Mashiah, M. 2012. Personal communication, October 2. Abstract available from first author.
10. New Mexico Department of Health, Medical Cannabis Program. 2011. Medical Cannabis Program Update for the Medical Advisory Board Meeting 10/19/11. Available at: http://www.health.state.nm.us/idb/medicalcannabis/Update%20for%20Medical%20Advisory%20Board%20Meeting%2010-19-11%20(2).pdf (accessed March 30, 2013).
11. New Mexico Department of Health, Medical Cannabis Program. 2012. Enrollment/Re-enrollment Medical Certification Form. Available at: http://nmhealth.org/mcp/documents/NMDOH-MCP-Form-PatientPacket.pdf (accessed March 30, 2013).
12. Pamplona, F.A.; Bitencourt, R.M. & Takahashi, R.N. 2008. Short- and long-term effects of cannabinoids on the extinction of contextual fear memory in rats. Neurobiology of Learning and Memory 90: 290-3.
13. Pamplona, F.A.; Prediger, R.D.; Pandolfo, P. & Takahashi, R.N. 2006. The cannabinoid receptor agonist WIN 55,212-2 facilitates the extinction of contextual fear memory and spatial memory in rats. Psychopharmacology 188: 641-9.
14. Passie, T.; Emrich, H.M.; Karst, M.; Brandt, S.D. & Halpern, J.H. 2012. Mitigation of post-traumatic stress symptoms by cannabis resin: A review of the clinical and neurobiological evidence. Drug Testing and Analysis 4 (7-8): 649-59.
15. Schier, A.R.; Ribeiro, N.P.; Silva, A.C.; Hallak, J.E.; Crippa, J.A.; Nardi, A.E. & Zuardi, A.W. 2012. Cannabidiol, a cannabis sativa constituent, as an anxiolytic drug. The Revista Brasileira de Psiquiatria 34 (suppl. 1): 104-10.
16. Weathers, F.W.; Keane, T.M. & Davidson, J.R.T. 2001. Clinician-administered PTSD scale: A review of the first ten years of research. Depression and Anxiety 13: 132-56.
17. Weathers, F.W.; Ruscio, A.M. & Keane, T.M. 1999. Psychometric properties of nine scoring rules for the clinician-administered posttraumatic stress disorder scale. Psychological Assessment 11 (2): 124-33.